Perioperative medicine & outcomes
Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial
Primary resultResult — go to the resultRelative risk 1.02 95% CI 0.87–1.19Authors' conclusion
Among patients who underwent major noncardiac surgery, a continuation strategy of RASIs before surgery was not associated with a higher rate of postoperative complications than a discontinuation strategy.
Study context
- Population
- Patients treated with a RASI for at least 3 months scheduled for major noncardiac surgery, 40 hospitals in France, 2018–2023
- Participants
- 2,222 patients
- Comparison
- Continuation vs discontinuation of renin-angiotensin system inhibitors (RASIs) before major noncardiac surgery
- RASI continuationn = 1,107
- RASI discontinuationn = 1,115reference
- Primary endpoint
- Composite of:
- All-cause mortality
- Major postoperative complications
- Follow-up
- 28 days after surgery
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
Relative risk
1.02
95% CI 0.87–1.19
P = 0.85
Events by treatment group
RASI continuation vs RASI discontinuation
RR 1.02 (95% CI 0.87–1.19); P = 0.85
Secondary outcomes
Other trial outcomes (AKI, postoperative organ failure, hospital and ICU LOS)
- No other differences in the trial outcomes
Safety
| Outcome | RASI continuation | RASI discontinuation | RR (95% CI) | |
|---|---|---|---|---|
| Episodes of hypotension during surgeryKey secondary outcome | 54% | 41% | 1.31 (1.19–1.44) | |
| 0.512Relative risk (log scale) |
Original publication
Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →